PT-141 Research Peptides

Yes. PT-141 is the development/research name for the active molecule bremelanotide. [S1] [S13]

The active molecule is bremelanotide, but Vyleesi is a specific FDA-approved sterile subcutaneous autoinjector formulation containing bremelanotide acetate. A research vial is not automatically equivalent. [S2] [S18]

No. They are closely related cyclic melanocortin peptides, but PT-141/bremelanotide has a different C-terminal form and is a distinct chemical entity. [S1] [S16]

In the United States it is approved for premenopausal women with acquired, generalised HSDD causing marked distress or interpersonal difficulty and not explained by another medical or psychiatric condition, relationship problem or medication/drug effect. [S2] [S15]

No. The pivotal population had a specific diagnosis of acquired, generalised HSDD and was premenopausal. The evidence should not be generalised to every cause of low desire or to postmenopausal women. [S2] [S4]

Yes. Earlier intranasal studies examined erectile responses in healthy men and selected men with erectile dysfunction, including sildenafil responders and nonresponders. These studies are separate from the later Vyleesi HSDD programme and do not create an authorised male indication. [S7] [S8]

Not significantly versus placebo. The successful co-primary endpoints were increased sexual-desire scores and reduced distress about low desire. [S2] [S4]

In the FDA label tables, mean desire scores improved by roughly 0.5–0.6 points with bremelanotide versus 0.2 with placebo, and distress scores fell by about 0.7 versus 0.4. The differences were statistically significant; independent authors have questioned how clinically meaningful some endpoint effects are. [S2] [S5]

The US label identifies nausea, flushing, injection-site reactions, headache and vomiting among common adverse reactions. It also warns about transient blood-pressure increases, heart-rate reductions and focal hyperpigmentation. [S2]

Vyleesi transiently raises blood pressure and lowers heart rate after dosing. The US product is contraindicated in uncontrolled hypertension or known cardiovascular disease. [S2]

The Vyleesi label states that it can slow gastric emptying and alter absorption of orally administered medicines, with a particularly important reduction in oral naltrexone exposure. [S2]

For the finished subcutaneous Vyleesi product, the mean terminal half-life is about 2.7 hours. An older intranasal study reported about 1.85–2.09 hours. Route and formulation should therefore be stated with any pharmacokinetic figure. [S2] [S7]

Targeted searches of the MHRA product-information route did not locate a UK-authorised PT-141, bremelanotide or Vyleesi medicine as of 22 September 2026. The US approval of Vyleesi does not establish UK approval. [S14] [S15]

No. Purity, identity, active-moiety amount, formulation, sterility, biological activity and regulatory authorisation are separate issues. Vyleesi is a defined finished medicinal product; an independently sold research vial requires its own evidence. [S2] [S17] [S18]